Skip To Main Content

Tumor Types

Investigational Therapies

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Showing 58 out of 58 results

Phase III

Breast

  • Giredestrant
    (SERD)

    (GDC-9545, RG6171)
    Breast
  • Inavolisib
    (PI3K alpha inhibitor)

    (GDC-0077, RG6114)
    Breast
  • Ipatasertib
    (AKT inhibitor)

    (RG7440, GDC-008)a
    Breast

Gastrointestinal

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Gastrointestinal
    Genitourinary
  • Tiragolumab
    (anti-TIGIT)

    (MTIG7192A, RG6058)
    Gastrointestinal
    Lung

Genitourinary

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Gastrointestinal
    Genitourinary

Hematology

Lung

Phase II

Gastrointestinal

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)
    Gastrointestinal
    Head Neck
    Hematology
  • PD-1 x LAG3

    (RG6139)
    Gastrointestinal
    Solid Tumor
  • PD-1 x TIM3

    (RG77679)
    Gastrointestinal

Head Neck

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)
    Gastrointestinal
    Head Neck
    Hematology
  • Tiragolumab
    (anti-TIGIT MAb)

    (RG6058, MTIG7192A)
    Head Neck
    Lung

Hematology

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)
    Gastrointestinal
    Head Neck
    Hematology
  • Glofitamab
    (CD20 x CD3)

    (RG6026)
    Hematology
  • Mosunetuzumab
    (CD20 x CD3)

    (RG7828)
    Hematology
  • Venetoclax
    (BCL-2 inhibitor)

    (ABT-199, RG7601)c
    Hematology

Lung

Solid Tumor

  • PD-1 x LAG3

    (RG6139)
    Gastrointestinal
    Solid Tumor

Phase I

Brain

Breast

  • Inavolisib
    (PI3K alpha inhibitor)

    (GDC-0077, RG6114)
    Breast
    Solid Tumor
  • Runimotamab
    (HER2 x CD3)

    (RG6194)
    Breast
    Gastrointestinal
    Solid Tumor

Gastrointestinal

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)
    Gastrointestinal
    Hematology
    Solid Tumor
  • Cibisatamab
    (CEA x CD3)

    (RG7802)
    Gastrointestinal
  • FAP x 4-1BBL

    (RG7827)
    Gastrointestinal
  • New molecular entity (NME)

    (RG6286)
    Gastrointestinal
  • Runimotamab
    (HER2 x CD3)

    (RG6194)
    Breast
    Gastrointestinal
    Solid Tumor

Hematology

Solid Tumor

No results were found


aDeveloped in collaboration with Array Biopharma.bDeveloped in collaboration with Exelixis. cJoint project with AbbVie. dDeveloped in collaboration with Xencor.
Current as of May 10, 2022. The trial information is taken from ClinicalTrials.gov.

    • Roche. 2022 Q1 results. April 25, 2022. Accessed May 10, 2022. https://www.roche.com/investors/updates/inv-update-2022-04-25

      Roche. 2022 Q1 results. April 25, 2022. Accessed May 10, 2022. https://www.roche.com/investors/updates/inv-update-2022-04-25